New drugs: rasagiline mesylate, conivaptan hydrochloride, and sunitinib malate.
Hussar
Daniel A
DA
Philadelphia College of Pharmacy, University of the Sciences, Philadelphia, PA, USA.
D065092:Antidiuretic Hormone Receptor Antagonists; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D001552:Benzazepines / Q000627:therapeutic use*; D017277:Drug Approval; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy; D006801:Humans; D007010:Hyponatremia / Q000188:drug therapy*; D007189:Indans / Q000627:therapeutic use*; D007211:Indoles / Q000627:therapeutic use*; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use; D011758:Pyrroles / Q000627:therapeutic use*; D000077210:Sunitinib; D014481:United States; D014486:United States Food and Drug Administration
D065092:Antidiuretic Hormone Receptor Antagonists; D000970:Antineoplastic Agents; D000978:Antiparkinson Agents; D001552:Benzazepines; D007189:Indans; D007211:Indoles; D008996:Monoamine Oxidase Inhibitors; D011758:Pyrroles; C031967:rasagiline; C106389:conivaptan; D000077210:Sunitinib